Algeta ASA : Algeta Results for the Third Quarter 2013
November 06, 2013 01:05 ET
|
Algeta ASA
OSLO, Norway, Nov. 6, 2013 (GLOBE NEWSWIRE) --
Intended for US media only
Algeta ASA (OSE: ALGETA), a company focused on
the development of novel targeted cancer therapeutics, announces its results...
Algeta to Participate in Upcoming Investor Conferences
November 05, 2013 01:06 ET
|
Algeta ASA
OSLO, Norway, Nov. 5, 2013 (GLOBE NEWSWIRE) --
Algeta ASA (OSE: ALGETA), a company focused on
the development of novel targeted cancer therapeutics, announces that members of
its executive management...
Algeta ASA : Net Sales of Xofigo (radium Ra 223 dichloride) Injection for Third Quarter 2013
October 31, 2013 03:06 ET
|
Algeta ASA
OSLO, Norway, Oct. 31, 2013 (GLOBE NEWSWIRE) --
Intended for US media only
Algeta ASA (OSE: ALGETA) announces that Bayer,
in its third quarter 2013 results presented today, disclosed that US net...
Algeta Schedules Third Quarter 2013 Results Presentation, Webcast and Conference Call
October 28, 2013 02:08 ET
|
Algeta ASA
OSLO, Norway, Oct. 28, 2013 (GLOBE NEWSWIRE) --
Algeta ASA (OSE: ALGETA), a company focused on
the development of novel targeted cancer therapeutics, will announce its third
quarter 2013 results on...
Algeta ASA : Xofigo(r) (radium Ra 223 dichloride) Injection Recommended for Approval in the European Union
September 20, 2013 08:24 ET
|
Algeta ASA
Intended for US media only
OSLO, Norway, Sept. 20, 2013 (GLOBE NEWSWIRE) -- Algeta ASA (OSE: ALGETA), announced today that Bayer has received a positive opinion from the European Medicines...
New data and analyses from the phase III ALSYMPCA trial of Xofigo(R) (radium Ra 223 dichloride) injection to be presented at the European Cancer Congress (ECCO-ESMO-ESTRO) 2013
September 12, 2013 04:18 ET
|
Algeta ASA
OSLO, Norway, Sept. 12, 2013 (GLOBE NEWSWIRE) --
Intended for US media only
Algeta ASA (OSE:ALGETA), announced today that
further analyses of data subsets from the phase III ALSYMPCA study of...